Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
| Revenue (TTM) | $46.59B |
| Gross Profit (TTM) | $26.48B |
| EBITDA | $11.68B |
| Operating Margin | 14.70% |
| Return on Equity | 10.60% |
| Return on Assets | 5.33% |
| Revenue/Share (TTM) | $26.76 |
| Book Value | $29.54 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | 3.76 |
| EV/Revenue | 4.424 |
| EV/EBITDA | 17.58 |
| Quarterly Earnings Growth (YoY) | -47.50% |
| Quarterly Revenue Growth (YoY) | 13.00% |
| Shares Outstanding | $1.73B |
| Float | $1.72B |
| % Insiders | 0.49% |
| % Institutions | 81.82% |
Volatility is currently contracting
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Abbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors Research shows registered dietitian-led medical nutrition therapy can improve glucose control and cardiometabolic health outcomes, highlighting the power of combining glucose data plus human expertise1 ABBOTT PARK, Ill. and NEW YORK, Sept.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.
Abbott Laboratories has agreed to pay more than $384 million to settle allegations related to contaminated infant formula, the U.S. Justice Department said on Monday.
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of unopened product from the homes of the infants under investigation at the time of the 2022 recall were negative for Cronobacter sakazakii No unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii ABBOTT PARK, Ill., Sept. 14, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorneys General of several states, relating to Abbott's manufacturing and 2022 recall of powdered infant formula at its facility in Sturgis, Mich.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABT and any ticker you trade — then tracks every position and per-strategy win rate.
